Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Wuchter

Showing results (71-80 of 111) with videos related to

Pageof 12
Sort By:
BMC Cancer|December 14, 2011
A phase II study evaluating neo-/adjuvant EIA chemotherapy, surgical resection and radiotherapy in high-risk soft tissue sarcomaThomas Schmitt, Burkhard Lehner, Bernd Kasper, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 10, 2015
Bone Marrow Harvesting of Allogeneic Donors in an Outpatient Setting: A Single-Center ExperienceKatharina Lisenko, Peter Stadtherr, Thomas Bruckner, et al.
Oncotarget|June 2, 2018
Survival outcomes of patients with germ cell tumors treated with high-dose chemotherapy for refractory or relapsing diseaseStefanie Zschäbitz, Florian A Distler, Benjamin Krieger, et al.
Cell and Tissue Research|March 21, 2007
Processus and recessus adhaerentes: giant adherens cell junction systems connect and attract human mesenchymal stem cellsPatrick Wuchter, Judit Boda-Heggemann, Beate K Straub, et al.
BMC Cancer|June 3, 2014
Excellent local control with IOERT and postoperative EBRT in high grade extremity sarcoma: results from a subgroup analysis of a prospective trialFalk Roeder, Burkhard Lehner, Thomas Schmitt, et al.
Cytotherapy|November 26, 2009
A combination of granulocyte-colony-stimulating factor (G-CSF) and plerixafor mobilizes more primitive peripheral blood progenitor cells than G-CSF alone: results of a European phase II studyStefan Fruehauf, Marlon Romano Veldwijk, Timon Seeger, et al.
Plos One|March 22, 2019
Diagnostic performance of the molecular BCR-ABL1 monitoring system may impact on inclusion of CML patients in stopping trialsBirgit Spiess, Sébastien Rinaldetti, Nicole Naumann, et al.
International Journal of Cancer|December 30, 2014
The rarity of ALDH(+) cells is the key to separation of normal versus leukemia stem cells by ALDH activity in AML patientsVan T Hoang, Eike C Buss, Wenwen Wang, et al.
Stem Cell Research|August 23, 2019
Mesenchymal stem cells preserve their stem cell traits after exposure to antimetabolite chemotherapyRamon Lopez Perez, Franziska Münz, Denise Vidoni, et al.
Transfusion|August 14, 2014
Plerixafor is effective given either preemptively or as a rescue strategy in poor stem cell mobilizing patients with multiple myelomaJian Cheng, Michael Schmitt, Patrick Wuchter, et al.
Pageof 12

Showing results (71-80 of 111) with videos related to

Sort By:
Pageof 12
BMC Cancer|December 14, 2011
A phase II study evaluating neo-/adjuvant EIA chemotherapy, surgical resection and radiotherapy in high-risk soft tissue sarcomaThomas Schmitt, Burkhard Lehner, Bernd Kasper, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 10, 2015
Bone Marrow Harvesting of Allogeneic Donors in an Outpatient Setting: A Single-Center ExperienceKatharina Lisenko, Peter Stadtherr, Thomas Bruckner, et al.
Oncotarget|June 2, 2018
Survival outcomes of patients with germ cell tumors treated with high-dose chemotherapy for refractory or relapsing diseaseStefanie Zschäbitz, Florian A Distler, Benjamin Krieger, et al.
Cell and Tissue Research|March 21, 2007
Processus and recessus adhaerentes: giant adherens cell junction systems connect and attract human mesenchymal stem cellsPatrick Wuchter, Judit Boda-Heggemann, Beate K Straub, et al.
BMC Cancer|June 3, 2014
Excellent local control with IOERT and postoperative EBRT in high grade extremity sarcoma: results from a subgroup analysis of a prospective trialFalk Roeder, Burkhard Lehner, Thomas Schmitt, et al.
Cytotherapy|November 26, 2009
A combination of granulocyte-colony-stimulating factor (G-CSF) and plerixafor mobilizes more primitive peripheral blood progenitor cells than G-CSF alone: results of a European phase II studyStefan Fruehauf, Marlon Romano Veldwijk, Timon Seeger, et al.
Plos One|March 22, 2019
Diagnostic performance of the molecular BCR-ABL1 monitoring system may impact on inclusion of CML patients in stopping trialsBirgit Spiess, Sébastien Rinaldetti, Nicole Naumann, et al.
International Journal of Cancer|December 30, 2014
The rarity of ALDH(+) cells is the key to separation of normal versus leukemia stem cells by ALDH activity in AML patientsVan T Hoang, Eike C Buss, Wenwen Wang, et al.
Stem Cell Research|August 23, 2019
Mesenchymal stem cells preserve their stem cell traits after exposure to antimetabolite chemotherapyRamon Lopez Perez, Franziska Münz, Denise Vidoni, et al.
Transfusion|August 14, 2014
Plerixafor is effective given either preemptively or as a rescue strategy in poor stem cell mobilizing patients with multiple myelomaJian Cheng, Michael Schmitt, Patrick Wuchter, et al.
Pageof 12